Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Videos

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Liso-cel vs Standard of Care With Salvage Chemotherapy Followed by ASCT as 2L Treatment in Patients With R/R LBCL: 3-year Follow-Up From Phase 3 TRANSFORM Study

Video Series

Safety Management and Monitoring Protocols for Liso-cel

Experts discuss the 3-year follow-up results from the phase 3 TRANSFORM study, comparing liso-cel with standard of care with salvage chemotherapy followed by autologous stem cell transplant (ASCT) as second-line treatment in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Experts provide a brief overview of the current treatment landscape and unmet needs in relapsed/refractory (R/R) large B-cell lymphoma.

Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma

Experts discuss the 3-year follow-up from the phase 3 TRANSFORM study, providing an overview of the study and key efficacy data.

Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

Experts discuss long-term efficacy and real-world outcomes with liso-cel in treating relapsed/refractory large B-cell lymphoma.

Long-Term Efficacy and Real-World Outcomes With Liso-cel

Experts discuss patient selection and timing considerations for chimeric antigen receptor T-cell (CAR T) therapy in treating relapsed/refractory large B-cell lymphoma.

Patient Selection and Timing Considerations for CAR T Therapy

Experts discuss the impact of manufacturing and treatment timing on patient outcomes for chimeric antigen receptor T-cell (CAR T) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL).

Impact of Manufacturing and Treatment Timing on Patient Outcomes for CAR T in R/R LBCL

Experts discuss clinical features and risk factors in navigating the decision between autologous stem cell transplant (ASCT) and chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL

Experts provide a safety summary of the phase 3 TRANSFORM study, highlighting key safety findings for liso-cel in relapsed/refractory large B-cell lymphoma.

TRANSFORM Safety Summary

Experts discuss safety management and monitoring protocols for liso-cel in treating relapsed/refractory large B-cell lymphoma.

Experts discuss future directions and key insights in treating large B-cell lymphoma (LBCL).

Future Directions and Key Insights in LBCL Treatment

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

Safety Management and Monitoring Protocols for Liso-cel

EP: 1.Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma

EP: 2.Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

EP: 3.Long-Term Efficacy and Real-World Outcomes With Liso-cel

EP: 4.Patient Selection and Timing Considerations for CAR T Therapy

EP: 5.Impact of Manufacturing and Treatment Timing on Patient Outcomes for CAR T in R/R LBCL

EP: 6.Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL

EP: 7.TRANSFORM Safety Summary

EP: 8.Safety Management and Monitoring Protocols for Liso-cel

EP: 9.Future Directions and Key Insights in LBCL Treatment